IRCT20180302038915N1已完成3 期
Evaluation of the Safety and Efficacy of Sofosbuvir in patients with moderate COVID19, A Single-blind, randomized controlled trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 80 years（—）
- 性别
- All
入选标准
- •Both genders Age ranging from18 to 80 Y.O. who are admitted in hospital
- •showing at least one of these criteria: Fever (Oral temperature = 38 ?) , Respiratory rate >24/min , O2Sat<93% in room air or the Pa02/Fi02 ratio =300mgHg
- •Laboratory (RT-PCR) confirming the infection with 2019-Covid Virus
- •Lung involvement in CT-Scan less than 50 % ( in compliance with the involvement of moderate COVID19 )
- •5 =days since onset of the COVID19 symptoms =10
排除标准
- •History of allergic reaction to the drugs used in this clinical trial
- •in a pregnancy or breast feeding status
- •test Receipt of any experimental treatment for COVID-19 before hand
- •Heart rate < 60/min
- •currently on amiodarone prescription
- •presence of multi organ failure evidence
- •in need of mechanical ventilation
- •estimated glomerular filtration rate < 50 0mL/1.73 m2/min
- •admitted in ICU ward
- •who are in shock
研究者
相似试验
Unknown
3 期
Role of anti Hepatitis C drug (Sofosbuvir and Ribavirin)in Liver disease.CTRI/2017/11/010373ATCO PHARMACEUTICALS62
招募中
不适用
Evaluation of the effectiveness and safety of Sofosbuvir plus Daclatasvir in the treatment for HCV or HIV/HCV with hemophiliaJPRN-UMIN000021544Tokyo Medical University20
招募中
2 期
?Effect of sofosbuvir/ ledipasvir on COVID-19COVID-19 pneumonia.IRCT20100228003449N29Tehran University of Medical Sciences50
招募中
2 期
Efficacy and safety of Sofosbuvir in the treatment of SARS-CoV-2: An Open Label phase II TrialSARS-CoV-2 ?associated SARI.SARS-CoV-2U07.1IRCT20200328046882N1Shahid Beheshti University of Medical Sciences60
进行中（未招募）
不适用
Study to assess efficacy and safety of Sofosbuvir/Ledipasvir (GS-5885) fixed-dose combination with Ribavirin in treatment experienced subjects with HCV genotype 1 infection and HIV co-infectioCoinfection with HCV genotype 1 and HIVEUCTR2013-002607-33-FRINSERM-ANRS